Mycoplasma Diagnostics Market 2016 Share, Trend and Forecast Mycoplasma Diagnostics Market - Global Industry An | Page 2

demand for PCR is forecast to increase considerably in the coming years owing to
the rising incidence of hospital acquired infections. The diagnostic technology
provides rapid turnaround time, reduction in cost of sequencing, and sensitivity. As
end users get to know benefits offered by PCR, the demand from the segment will
increase in response.
By end users, global mycoplasma diagnostic market is dominated by hospitals &
diagnostic laboratories. Hospitals & diagnostic laboratories are an important
channel for the usage of multiplexed diagnostic products & offer a range of
diagnosis solutions. They are an important channel for the usage of multiplexed
diagnostic products. According to the norms of government health care facilities,
they offer reimbursement plans and advanced technology systems for treatment.
Get accurate market forecast and analysis on the Mycoplasma Diagnostics
Market Request a sample to stay abreast on the key trends impacting this
market.
http://www.transparencymarketresearch.com/sample/sample.php?
flag=S&rep_id=1677
North America Holds Dominance, But Asia Pacific to Report Higher CAGR
Regionally, North America, Asia Pacific, Europe, Latin America, and the Middle East
and Africa constitute the key market segments. Among these regions, North
America held dominance in 2016 with an estimated share of 35.4% in the overall
market. Several large research laboratories are present in North America. Besides
this, the region also boasts a high level of public awareness, which provides an
environment conducive to the growth of the mycoplasma diagnostics market.
Furthermore, in the coming years, the market is expected to gain from the
increasing demand for point of care testing.
Despite dominance exercised by the North America market, during the forecast
period Asia Pacific will showcase more lucrative opportunities. Besides the high
incidence of respiratory tract infection witnessed in the last few years, the emerging
nations in the region boasts high healthcare spending, which has helped the
mycoplasma market exhibit strong growth in Asia Pacific. In addition, the regional
market is forecast to gain from the rising demand for personalized medicines, rise in
research and development investments, and the rising public awareness.
Key players operating in this market include F. Hoffmann-La Roche Ltd., Agilent
Technologies, Sartorius Stedim BioOutsource Limited, Savyon Diagnostics, Takara
Bio Inc. (Takara Holding Company Inc.), Lonza Group, Merck KGaA, and Charles River
Laboratories International, Inc. among others.
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global
business information reports and services. Our exclusive blend of quantitative forecasting and